Barclays PLC Immunity Bio, Inc. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 927,687 shares of IBRX stock, worth $1.93 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
927,687
Previous 839,894
10.45%
Holding current value
$1.93 Million
Previous $2.22 Million
2.93%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding IBRX
# of Institutions
299Shares Held
137MCall Options Held
2.59MPut Options Held
3.35M-
Vanguard Group Inc Valley Forge, PA27.7MShares$57.5 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY12.8MShares$26.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$23.8 Million0.0% of portfolio
-
State Street Corp Boston, MA11.3MShares$23.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$14.3 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $833M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...